Nafamostat mesilate reduces blood-foreign surface reactions similar to biocompatible materials.

[1]  R. Colman,et al.  Nafamostat Mesilate, a Broad Spectrum Protease Inhibitor, Modulates Platelet, Neutrophil and Contact Activation in Simulated Extracorporeal Circulation , 1996, Thrombosis and Haemostasis.

[2]  A. Usui,et al.  Nafamostat Mesilate Reduces Blood Loss During Open Heart Surgery , 1993, Circulation.

[3]  M. Turina,et al.  Reduction and elimination of systemic heparinization during cardiopulmonary bypass. , 1992, The Journal of thoracic and cardiovascular surgery.

[4]  V. Videm,et al.  Biocompatibility of extracorporeal circulation. In vitro comparison of heparin-coated and uncoated oxygenator circuits. , 1991, The Journal of thoracic and cardiovascular surgery.

[5]  H. Nagaoka,et al.  Effects of aprotinin on prostaglandin metabolism and platelet function in open heart surgery. , 1991, The Journal of cardiovascular surgery.

[6]  M. Jochum,et al.  Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. , 1990, Anesthesiology.

[7]  R. Colman,et al.  Formation of C1s-C1-inhibitor, kallikrein-C1-inhibitor, and plasmin-alpha 2-plasmin-inhibitor complexes during cardiopulmonary bypass. , 1989, Blood.

[8]  Charles R.scriver,et al.  The Metabolic basis of inherited disease , 1989 .

[9]  A. Schmaier,et al.  Fibrinogen receptors in platelet adhesion to surfaces of extracorporeal circuit. , 1987, The American journal of physiology.

[10]  H. Kwaan,et al.  Increased fibrinolytic activity in patients undergoing cardiopulmonary bypass operation , 1986, American journal of hematology.

[11]  S. Fujii,et al.  Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system. , 1985, Haemostasis.

[12]  R. Colman,et al.  Loss of fibrinogen receptors from the platelet surface during simulated extracorporeal circulation. , 1985, The Journal of laboratory and clinical medicine.

[13]  T. Sato,et al.  Pharmacological studies of FUT-175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments. , 1984, Japanese journal of pharmacology.

[14]  S. Fujii,et al.  Inhibition of various immunological reactions in vivo by a new synthetic complement inhibitor. , 1982, International archives of allergy and applied immunology.

[15]  R. Colman,et al.  Platelet function during cardiac operation: comparison of membrane and bubble oxygenators. , 1982, The Journal of thoracic and cardiovascular surgery.

[16]  S. Fujii,et al.  New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. , 1981, Biochimica et biophysica acta.

[17]  E. Hessel,et al.  Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. , 1980, Blood.

[18]  R. Colman,et al.  Thromboxane synthesis and platelet secretion during cardiopulmonary bypass with bubble oxygenator. , 1980, The Journal of thoracic and cardiovascular surgery.

[19]  R. Clauss,et al.  HEMORRHAGE DUE TO FIBRINOLYSIS OCCURRING WITH OPEN-HEART OPERATIONS. , 1963, The Journal of thoracic and cardiovascular surgery.